GERON CORP Deferred Tax Assets, Operating Loss Carryforwards
GERON CORP (GERN) had Deferred Tax Assets, Operating Loss Carryforwards of $278.38 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $278.38M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $272.97M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $272.30M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $254.50M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $278.38M 10-K · filed 2026-03-02 |
| 2024-12-31 | $272.97M 10-K · filed 2026-03-02 |
| 2023-12-31 | $272.30M 10-K · filed 2025-02-27 |
| 2022-12-31 | $254.50M 10-K · filed 2024-02-28 |
| 2021-12-31 | $241.30M 10-K · filed 2023-03-16 |
| 2020-12-31 | $217.10M 10-K · filed 2022-03-10 |
| 2019-12-31 | $204.60M 10-K · filed 2021-03-11 |
| 2018-12-31 | $192.10M 10-K · filed 2020-03-12 |
| 2017-12-31 | $187.70M 10-K · filed 2019-03-07 |
| 2016-12-31 | $280.40M 10-K · filed 2018-03-16 |
| 2015-12-31 | $276.10M 10-K · filed 2017-03-01 |
| 2014-12-31 | $281.30M 10-K · filed 2016-03-10 |
| 2013-12-31 | $271.80M 10-K · filed 2015-03-11 |
| 2012-12-31 | $248.70M 10-K · filed 2014-03-17 |
| 2011-12-31 | $230.20M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |